HEOR & market access
At Aixial Group, our Health Economic and Outcome Research (HEOR) & Market Access experts help sponsors generate meaningful evidence, address evolving payer requirements and support patient access to innovative healthcare solutions.
Generating the evidence that supports healthcare decisions
Demonstrating the value of healthcare innovation requires more than proving safety and efficacy. Healthcare authorities, Health Technology Assessment (HTA) bodies, and payers increasingly expect robust clinical, patient-centered, and economic evidence to support reimbursement and access decisions.
Combining expertise in HEOR, biostatistics, health economics, and evidence generation, Aixial supports pharmaceutical companies throughout the product lifecycle, from clinical development to HTA submissions and post-launch evidence generation.
Supporting access to innovation
Healthcare systems worldwide face increasing pressure to balance innovation, affordability, and patient outcomes. Payers are demanding stronger evidence to support funding decisions, while sponsors must demonstrate the real-world value of increasingly complex therapies.
From orphan drugs and oncology treatments to advanced therapies and precision medicine, HEOR and Market Access have become essential components of successful product development strategies. Our experts help sponsors anticipate challenges, generate relevant evidence, and communicate product value effectively to key decision-makers.
Our expertise
Evidence generation & evidence synthesis
Our teams design, generate and synthesize evidence to support HTA assessments, reimbursement decisions and healthcare decision-making throughout the product lifecycle.
Key capabilities
- Systematic and Targeted Literrature Review (SLR & TLR)
- Indirect Treatment Comparison (ITC) & Network-Meta-Analysis (NMA)
- Burden of illness studies
- Healthcare Resource Utilization (HCRU) studies
- Real World Evidence (RWE) analyses
Biostatistics & outcomes research
Our biostatisticians and statistical programmers support sponsors with robust analyses that strengthen clinical development, outcomes research and evidence generation strategies.
Key capabilities
- Advanced statistical analyses
- Statistical Analysis Plan (SAP) development and review
- Clinical Outcome Assessment (COA) and Patient Reported Outcome (PRO) analyses
- Real-world data analyses
- Outcomes research
Health economics & economic modelling
We develop and support economic evaluations that help translate clinical outcomes into economic value meaningful to healthcare decision-makers. Through economic modelling, budget impact assessments and cost-effectiveness analyses, we provide robust evidence to support reimbursement discussions and value communication.
Key capabilities
- Cost-effectiveness analyses
- Cost-utility analyses
- Budget impact models
- Economic evaluations
- Scenario and sensitivity analyses
HTA & value demonstration
Our teams contribute to the development of evidence packages designed to meet HTA and reimbursement requirements at both European and local levels.
Key capabilities
- HTA submission support
- Core Value Dossiers
- Evidence planning
- Value communication
- EU Joint Clinical Assessments (JCA) support
Looking for a HEOR & market access expertise ?
Transforming data into evidence, evidence into value, and value into patient access.
At Aixial, our mission goes beyond clinical development. We help transform evidence into access and innovation into patient benefit.
By combining HEOR expertise, market access strategy, and deep clinical development knowledge, we support sponsors in making informed decisions, accelerating market adoption, and ensuring innovative therapies reach the patients who need them most.
Tailored collaboration models
Functional service provision
We have extensive experience in governance, management, and partnership as an FSP provider. Our approach is tailored to your requirements and adapts as the partnership evolves.
Consulting support
Flexible expert services delivered on demand to address specific challenges, support projects, and strengthen your operations.
Q&A
Why is HEOR important in drug development?
HEOR helps pharmaceutical and biotech companies demonstrate the value of their products beyond clinical efficacy and safety. It supports reimbursement submissions, pricing strategies, market access activities, and informed healthcare decision-making.
At what stage of development should HEOR activities begin?
HEOR should be integrated as early as possible in the product development process. Early planning helps identify evidence needs, optimize clinical development programs, and build a strong value proposition for future reimbursement and market access success.
How does HEOR support Market Access?
HEOR provides the evidence required to demonstrate the clinical and economic value of a therapy. Through health economic models, real-world evidence, patient-reported outcomes, and burden-of-illness studies, HEOR strengthens market access and reimbursement applications.
What operational models do you offer ?
To match your internal infrastructure and budget, we offer flexible delivery models:
Functional Service Provision (FSP): We have extensive experience in governance, management, and partnership as an FSP provider. Our approach is tailored to your requirements and adapts as the partnership evolves.
Consulting & operational support: Flexible expert services delivered on demand to address specific challenges, support projects, and strengthen your operations.
Why choose Aixial for HEOR & Market Access consulting?
Aixial combines scientific expertise, strategic insight, and operational excellence to help clients generate robust evidence, maximize product value, and accelerate patient access across global healthcare markets.
How can we support your next project?
Whether you’re looking for a protocol review or a proposal,
simply reach out to us by filling our request for proposal.
